Pristimerin has been reported to increase the levels of p-JNK and p-p38, whereas decrease the levels of p-ERK in MDA-MB-231 and MDA-MB-468 breast cancer cells (21), and K562 CML cells (39). Here, MAPK8 is linked to breast cancer.